Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1537-1545

  Swallow, Elyse ^a   Zhang, Jie ^b   Thomason, Darren ^a   Tan, Ruo Ding ^a   Kageleiry, Andrew ^a   Signorovitch, James ^a  

^a ANALYSIS GROUP   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; Endocrine therapy; Treatment patterns

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE; HORMONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; TREATMENT PLANNING; UNITED STATES; AGED; BREAST NEOPLASMS; CLINICAL PRACTICE; DRUG ADMINISTRATION; FACTUAL DATABASE; METABOLISM; METASTASIS; PATHOLOGY; POSTMENOPAUSE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84904885985     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.908829     Document Type: Article

References (34)

1. Breast Cancer Statistics. Division for Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion. Atlanta, GA: Centers for Disease Control and Prevention, 2013. Available at: http://www.cdc.gov/cancer/breast/statistics/[Last accessed 23 December 2013]
2. Cancer Facts & Figures 2012. American Cancer Society. Atlanta GA: American Cancer Society; 2013. Available at: http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc- 031941.pdf [Last accessed 23 December 2013]
3. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-9
4. Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22
5. Ries LAG, Young JL, Keel GE, et al. (eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, 2007
6. Chung C, Carlson R. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003;8:514-20
7. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Onco 2006;33:2-5
8. Trivers K, Lund M, Porter P, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Cause Control 2009;20:1071-82
9. Hormone Therapy for Breast Cancer. National Cancer Institute Fact Sheet. Bethesda, MD: National Cancer Institute, 2012. Available at: http://www.cancer. gov/cancertopics/factsheet/Therapy/hormone-therapy-breast [Last accessed 20 December 2012]
10. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52
11. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 1. 2014. Fort Washington, PA: National Comprehensive Cancer Network. Available at www.nccn.com [Last accessed 27 January 2014]
12. Booth C, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007;5:374-80
13. Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcome 2003;1:46
14. Partridge A, Burstein H, Winer E. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001;(30):135-42
15. Hershman D, Kushi L, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Onco 2010;28:4120-8
16. Hadji P, Ziller V, Kyvernitakis J, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013;138:185-91
17. Barron T, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109:832-9
18. McCowan C, Shearer J, Donnan P, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-8
19. Whyte J, Engel-Nitz N, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care 2013: published online 21 March 2013, doi: 10.1097/MLR.0b013e318289c3fb
20. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab- based therapy. Oncologist 2006;11(Suppl 1):34-41
21. Wilson P, Garrison R, Castelli W. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. New Engl J Med 1985;313:1038-43
22. Carlson R, Henderson I. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003,80(Suppl 1):S19-26.
23. Mouridsen H, Keshaviah A, Coates A, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25: 5715-22
24. Johnston S, Kilburn L, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013;14:989-98
25. Kubota O, Onuki Y, Uchiyama T, et al. Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor. Gan to kagaku ryoho Cancer & Chemotherapy 2012;39:753-7
26. Fiorica J, Brunetto V, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10-14
27. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012;13:345-52.
28. Raloxifene hydrochloride tablets (EVISTA, Eli Lilly and Company), FDA/Center for Drug Evaluation and Research. Washington, DC. Available at: http://www.accessdata.fda.gov/drugsatfdadocs/label/2007/022042lbl.pdf [Last accessed 17 February 2014]
29. Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 2010;107:85-91
30. Sledge G, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92
31. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20: 2812-23
32. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-61
33. André F, Neven P, Marinsek N, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin 2014;30:1007-16
34. Hao Y, Engel-Nitz N, Rey G. Chemotherapy and endocrine therapy treatment patterns among patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer. Poster session presented at: The San Antonio Breast Cancer Symposium, 10-14 December 2013, San Antonio, TX, USA